http://www.xconomy.com/san-diego/2009/01/27/pfizer-wyeth-combos-impact-on-san-diego-biotech-bad-for-dealmaking-good-for-shareholders/ Business + Technology in the Exponential Economy Sat, 11 Feb 2012 09:14:03 +0000 hourly 1 http://wordpress.org/?v=3.0.4 http://www.xconomy.com/san-diego/2009/01/27/pfizer-wyeth-combos-impact-on-san-diego-biotech-bad-for-dealmaking-good-for-shareholders/comment-page-1/#comment-45200 RockyRadar Introduces “What We’re Reading” Friday post | On the Radar... Fri, 30 Jan 2009 22:20:59 +0000 http://www.xconomy.com/?p=10240#comment-45200 [...] have been mixed so far with FierceBiotech and the New York Times seeing limited impact and answers all over the board coming from several southern California biotech executives. Bookmark the permalink. Post a [...] [...] have been mixed so far with FierceBiotech and the New York Times seeing limited impact and answers all over the board coming from several southern California biotech executives. Bookmark the permalink. Post a [...]

]]> http://www.xconomy.com/san-diego/2009/01/27/pfizer-wyeth-combos-impact-on-san-diego-biotech-bad-for-dealmaking-good-for-shareholders/comment-page-1/#comment-45011 MedCity morning ready, Tuesday, Jan. 26 : MedCity News Tue, 27 Jan 2009 11:58:45 +0000 http://www.xconomy.com/?p=10240#comment-45011 [...] Xanthopoulos, chief executive of California’s Regulus Therapeutics, told Xconomy: “I think, at first passing, that this will be bad for biotechs which have traditionally used Big [...] [...] Xanthopoulos, chief executive of California’s Regulus Therapeutics, told Xconomy: “I think, at first passing, that this will be bad for biotechs which have traditionally used Big [...]

]]>